In Atlanta, Medical Sleuths Of Last Resort A program at the Centers for Disease Control and Prevention tries to identify killer pathogens, when all else has failed.... Read Full Article Stocks Fall On Fresh Woes In Banking Sector The retreat, which sent the Dow tumbling below 13,000, started after Citigroup was downgraded today to ’sell? by a Goldman Sachs analyst.... Read Full Article World Briefing | Europe: Spain: ETA Blamed For Blast Outside Police Station Two police officers were wounded by flying glass when a huge bomb exploded in the middle of the night outside a barracks in the Basque country town of Durango.... Read Full Article Opera Review | ’Cavalleria Rusticana ,’ ’Pagliacci’: In Opera’s Famous Pair Of One-Acts, Tenor Doubles His Workload Salvatore Licitra added ?Cavalleria Rusticana? to an already strenuous ?Pagliacci.?... Read Full Article North Korea Threatens To Reduce South Korea To ?Ashes? At Slightest Provocation The warning, one of the harshest in years, was a response to a statement by Kim Tae-young, the head of South Korea’s Joint Chiefs of Staff.... Read Full Article |
Ranbaxy NewsAstraZeneca Settles Ranbaxy LawsuitAstraZeneca shares soared on news that an agreement with Ranbaxy Laboratories will delay the release of a generic competitor to its best-selling heartburn drug for six years.Read Full Article World Business Briefing: India: Profit Doubles at Drug MakerThe Indian pharmaceutical company Ranbaxy Laboratories said its profit in the latest quarter more than doubled from a year ago, helped by robust sales in Europe and huge gains in foreign exchange transactions. Net profit at Ranbaxy rose to 2.66 billion rupees ($65 million), from 1.22 billion rupees ($29 million) in the quarter a year earlier. The growth rate, however, drops to 53 percent if the earnings numbers are adjusted against about 1 billion rupees in net gains the company made from foreign exchange transactions, said Malvinder Singh, the chief executive. More than half of Ranbaxy’s sales come from overseas markets other than the United States. Sales rose 12.3 percent, to 16.24 billion rupees ($395 million).Read Full Article World Business Briefing | Europe: Germany: Bid to Acquire Drug Maker’s Generic UnitAn Indian drug maker, Ranbaxy Laboratories, said it had submitted a bid for the generics unit of the German drug maker Merck but did not disclose how much it was offering. Analysts say Merck’s generics unit could be worth as much as 5 billion euros ($6.6 billion). Merck said last month that it had started contacting companies that might be interested in acquiring its generics drugs unit. Two companies, Ranbaxy and the Actavis Group of Iceland, have publicly expressed an interest. Merck is based in Darmstadt.Read Full Article F.D.A. Searches Drug Maker OfficesThe generic drug developer Ranbaxy Laboratories of India said Thursday that federal agents had searched its offices and a manufacturing facility in New Jersey.Read Full Article External News for: ranbaxyDr Reddy's files for marketing Lipitor generic - ReutersDr Reddy's files for marketing Lipitor genericReutersSo far, Ranbaxy (RANB.BO) is the only other Indian drugmaker to develop a generic for the drug, whose US patent expires in 2010. ...Generics Makers Line Up To Sell Copies Of Pfizer's LipitorCNNMoney.comDr Reddy's develops generic version of Pfizer's LipitorBusiness StandardDr Reddy's seeks US marketing rights for `Lipitor' genericdomain-BDTC Perspectives Magazine -Research Oracleall 25 news articles »Dr Reddy's files for marketing Lipitor generic - ReutersDr Reddy's files for marketing Lipitor genericReutersSo far, Ranbaxy (RANB.BO) is the only other Indian drugmaker to develop a generic for the drug, whose US patent expires in 2010. ...Generics Makers Line Up To Sell Copies Of Pfizer's LipitorCNNMoney.comDr Reddy's develops generic version of Pfizer's LipitorBusiness StandardDr Reddy's seeks US marketing rights for `Lipitor' genericdomain-BDTC Perspectives Magazine -Research Oracleall 25 news articles »Ranbaxy Posts Profit on Lower Costs, Currencies - BloombergAFPRanbaxy Posts Profit on Lower Costs, CurrenciesBloombergDemand in India, South Africa and other emerging markets, responsible for 62 percent of revenue, helped Ranbaxy offset a sales decline in the US, ...UPDATE 1-India Ranbaxy posts Q3 profit, keeps '09 loss f'castReutersIndia's Ranbaxy posts profit despite US import banBusinessWeekIndian drug firm Ranbaxy switches into profitAFPLivemint -Business Standard -Hindu Business Lineall 51 news articles »Dr Reddy's files for marketing Lipitor generic - ReutersDr Reddy's files for marketing Lipitor genericReutersSo far, Ranbaxy (RANB.BO) is the only other Indian drugmaker to develop a generic for the drug, whose US patent expires in 2010. ...Generics Makers Line Up To Sell Copies Of Pfizer's LipitorCNNMoney.comDr Reddy's develops generic version of Pfizer's LipitorBusiness StandardDr Reddy's seeks US marketing rights for `Lipitor' genericdomain-BDTC Perspectives Magazine -Research Oracleall 25 news articles »Ranbaxy Posts Profit on Lower Costs, Currencies - BloombergAFPRanbaxy Posts Profit on Lower Costs, CurrenciesBloombergDemand in India, South Africa and other emerging markets, responsible for 62 percent of revenue, helped Ranbaxy offset a sales decline in the US, ...UPDATE 1-India Ranbaxy posts Q3 profit, keeps '09 loss f'castReutersIndia's Ranbaxy posts profit despite US import banBusinessWeekIndian drug firm Ranbaxy switches into profitAFPLivemint -Business Standard -Hindu Business Lineall 51 news articles »Ranbaxy Beats 3Q Net Profit Forecast; Sales Decline - Wall Street JournalRanbaxy Beats 3Q Net Profit Forecast; Sales DeclineWall Street JournalBANGALORE (Dow Jones)--Ranbaxy Laboratories Ltd. (500359.BY) Monday posted a higher-than-expected consolidated net profit in the third ...Ranbaxy profits up but US sales still sufferingPharma TimesRanbaxy 3Q Net Profit Beats Forecast, Sales FallWall Street Journalall 3 news articles » |
i8news.com |
